Loading…
Dixon Investments Inc. dba ARI, a drug manufacturer in Georgia, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals during an FDA inspection in March 2025, resulting in adulterated and unapproved drug products. The company's critical violations included failure to establish adequate written procedures for production and process control to ensure drug products met their identity, strength, quality, and purity standards, as well as failure to perform process validation for over-the-counter products. The manufactured drugs were also found to be misbranded under federal regulations, with the company introducing these non-compliant products into interstate commerce.